RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+33.89%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.72B
AUM Growth
+$2.72B
(-2.6%)
Cap. Flow
-$414M
Cap. Flow
% of AUM
-15.2%
Top 10 Holdings %
Top 10 Hldgs %
41.91%
Holding
86
New
16
Increased
22
Reduced
27
Closed
9
Top Buys
| 1 |
SLN
Silence Therapeutics
SLN
|
$43.8M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$40.2M |
| 3 |
Keros Therapeutics
KROS
|
$36.6M |
| 4 |
Stoke Therapeutics
STOK
|
$33M |
| 5 |
Immunome
IMNM
|
$24.9M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$487M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$115M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$67.7M |
| 4 |
Krystal Biotech
KRYS
|
$40M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$26.4M |
Sector Composition
| 1 | Healthcare | 97.54% |
| 2 | Industrials | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Ventyx Biosciences
VTYX
$184M
| $11.9M | 0.44% |
2,164,126
+1,956,923
| +944% | +$10.8M |
|
52
Intuitive Surgical
ISRG
$158B
| $11.8M | 0.43% |
29,546
-24,712
| -46% | -$9.86M |
|
53
Cytokinetics
CYTK
$5.98B
| $11.3M | 0.42% |
+161,600
| New | +$11.3M |
|
54
Quest Diagnostics
DGX
$20.1B
| $11.2M | 0.41% |
+83,849
| New | +$11.2M |
|
55
McKesson
MCK
$85.9B
| $11.1M | 0.41% |
+20,707
| New | +$11.1M |
|
56
Nuvation Bio
NUVB
$1.08B
| $11M | 0.4% |
3,031,009
| – | – |
|
57
Elanco Animal Health
ELAN
$8.62B
| $11M | 0.4% |
+676,039
| New | +$11M |
|
|
BPMC
58
DELISTED
Blueprint Medicines
BPMC
| $10.7M | 0.39% |
+113,060
| New | +$10.7M |
|
59
Penumbra
PEN
$10.5B
| $9.96M | 0.37% |
44,613
-50,629
| -53% | -$11.3M |
|
60
Repare Therapeutics
RPTX
$73.9M
| $9.5M | 0.35% |
2,016,302
-132,446
| -6% | -$624K |
|
61
Apellis Pharmaceuticals
APLS
$3.51B
| $9.11M | 0.33% |
+155,000
| New | +$9.11M |
|
62
Stereotaxis
STXS
$246M
| $8.64M | 0.32% |
3,308,798
-93,645
| -3% | -$244K |
|
63
Cabaletta Bio
CABA
$144M
| $7.55M | 0.28% |
442,826
-931,363
| -68% | -$15.9M |
|
64
LAVA Therapeutics
LVTX
$41.3M
| $6.91M | 0.25% |
2,074,372
| – | – |
|
65
Atara Biotherapeutics
ATRA
$88.7M
| $6.43M | 0.24% |
9,263,309
+156,863
| +2% | +$109K |
|
66
Invivyd
IVVD
$218M
| $6.4M | 0.23% |
1,440,725
| – | – |
|
67
RAPT Therapeutics
RAPT
$187M
| $5.95M | 0.22% |
662,398
+295,622
| +81% | +$2.65M |
|
68
AC Immune
ACIU
$227M
| $5.94M | 0.22% |
2,007,031
+7,031
| +0.4% | +$20.8K |
|
69
Establishment Labs
ESTA
$1.11B
| $5.82M | 0.21% |
+114,341
| New | +$5.82M |
|
|
ALLK
70
DELISTED
Allakos
ALLK
| $4.35M | 0.16% |
3,451,076
-219,371
| -6% | -$276K |
|
71
Xeris Biopharma Holdings
XERS
$1.27B
| $2.31M | 0.08% |
1,046,587
| – | – |
|
|
ACHL
72
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $2.01M | 0.07% |
1,608,089
| – | – |
|
|
KLRS
73
Kalaris Therapeutics, Inc. Common Stock
KLRS
$85.5M
| $1.44M | 0.05% |
1,907,969
| – | – |
|
|
ADAP
74
Adaptimmune Therapeutics
ADAP
$13.9M
| $1.13M | 0.04% |
715,607
| – | – |
|
75
Standard BioTools
LAB
$493M
| $1.12M | 0.04% |
+411,631
| New | +$1.12M |
|